Zynerba Pharmaceuticals announces top-line results from phase 2 STAR 1 trial of ZYN002 in adult epilepsy patients with focal seizures
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializ...